Back to Journals » OncoTargets and Therapy » Volume 7

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Authors Jiang J, Wang G, Lv L, Liu CG, Liang X, Zhao H

Received 16 January 2014

Accepted for publication 21 February 2014

Published 6 May 2014 Volume 2014:7 Pages 663—666

DOI https://doi.org/10.2147/OTT.S60782

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Jian Jiang,1 Guixin Wang,1 Li Lv,2 Caigang Liu,1 Xi Liang,1 Haidong Zhao1

1Department of Breast Surgery, 2Department of Pathology, the Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China

Abstract: In this case study and review, we present a case of a primary small-cell neuroendocrine carcinoma (SCNC) of the male breast. Primary SCNC of the breast is a rare tumor with less than 30 cases reported in the literature. Most cases are found in women. Another exceptional point is that human epidermal growth factor receptor-2 (Her-2) immunoreactivity was positive in our recent case, which differed to previous reports detailing SCNC in women. We have no evidence to demonstrate the differences between treatment and prognoses for males and females, because we do not have sufficient cases to undertake an evidence-based investigation. We provide this rare case history; review the literature on SCNC of the breast; and discuss detailed information regarding epidemiology, histogenesis, clinical and histologic diagnosis criteria, surgical and adjuvant treatment, and prognosis.

Keywords: small-cell carcinoma, SMCC, neuroendocrine, male breast cancer, SCNC neoplasm

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]